Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the removal of a forecast for SERENA-4. Despite positive trial outcomes, AstraZeneca shares have fallen 15% year-to-date, with investors now focused on the upcoming AVANZAR trial, where Citigroup expects strong survival benefits to support further gains.
AstraZeneca shares are trading at USD 158.45 on Pluang, up 1.23% as of Oct 07, 2026 02:11 WIB, despite a 15% year-to-date decline noted in the article. The stock shows strong investor interest with 100% buy orders on the platform and a dividend yield of 2.05%. Citigroup, which raised the price target, is trading at USD 128.12, down 0.35% on the same day, with a majority of Pluang users selling its shares.
Citi has increased its target price for AstraZeneca to £186 from £178, maintaining a 'buy' rating after positive clinical developments, especially for the drug tozorakimab. The broker raised peak sales forecasts for tozorakimab to $7 billion and SERE...
AstraZeneca announced a $2 billion equity investment and clinical collaboration with Summit Therapeutics to develop ivonescimab, a first-in-class bispecific antibody for cancer treatment. This drug targets two cancer pathways simultaneously, potentia...
